TD Cowen Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Phil Nadeau maintains a Buy rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowers the price target from $125 to $120.
August 06, 2024 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen analyst Phil Nadeau maintains a Buy rating on Biomarin Pharmaceutical but lowers the price target from $125 to $120.
The Buy rating suggests continued confidence in Biomarin's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100